Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Elutia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aziyo Biologics Provides Update on FDA Submission for CanGaroo\u00ae RM Antibacterial Envelope","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Elutia","sponsor":"Berkeley Biologics","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"$35.0 million","newsHeadline":"Elutia Announces Sale of Orthobiologics Business Unit for Cash Proceeds of up to $35 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Elutia","sponsor":"HighCape Capital","pharmaFlowCategory":"D","amount":"$26.2 million","upfrontCash":"Undisclosed","newsHeadline":"Elutia Announces Private Placement for Proceeds up to $26 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Elutia","sponsor":"Berkeley Biologics","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"$35.0 million","newsHeadline":"Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of up to $35 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Elutia

    Menu

    Elutia

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Elutia

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of up to $35 Million

              Details:

              Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protection.

              Lead Product(s): Rifampicin,Minocycline Hydrochloride

              Therapeutic Area: Infections and Infectious Diseases Product Name: CanGaroo RM

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Berkeley Biologics

              Deal Size: $35.0 million Upfront Cash: $35.0 million

              Deal Type: Divestment November 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Elutia

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Elutia Announces Private Placement for Proceeds up to $26 Million

              Details:

              The net proceeds will support the Company’s advancement of its drug-eluting biomatrix products, including CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protection.

              Lead Product(s): Rifampicin,Minocycline Hydrochloride

              Therapeutic Area: Infections and Infectious Diseases Product Name: CanGaroo

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: HighCape Capital

              Deal Size: $26.2 million Upfront Cash: Undisclosed

              Deal Type: Private Placement September 19, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Elutia

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Elutia Announces Sale of Orthobiologics Business Unit for Cash Proceeds of up to $35 Million

              Details:

              Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protection.

              Lead Product(s): Rifampicin,Minocycline Hydrochloride

              Therapeutic Area: Infections and Infectious Diseases Product Name: CanGaroo

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Berkeley Biologics

              Deal Size: $35.0 million Upfront Cash: $35.0 million

              Deal Type: Divestment September 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Elutia

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aziyo Biologics Provides Update on FDA Submission for CanGaroo® RM Antibacterial Envelope

              Details:

              CanGaroo RM Antibacterial Envelope contains the antibiotics rifampin and minocycline, which have been shown in preclinical testing to reduce bacterial colonization on the envelope.

              Lead Product(s): Rifampicin,Minocycline Hydrochloride

              Therapeutic Area: Infections and Infectious Diseases Product Name: CanGaroo

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY